ZBTB11 Depletion Targets Metabolic Vulnerabilities in K-Ras Inhibitor Resistant PDAC [CRISPRi RNA-seq]
RNA-seq (gene expression) · human · 70 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Pancreatic cancerThis series is part of our curated briefing on it.
- Samples
- 70 samples: 24 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- ZBTB11 depletion targets metabolic vulnerabilities in KRAS inhibitor-resistant PDACNature chemical biology · 2026
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE298803_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1271331 and SRA study SRP589514. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 70 samples.
How we read this: 24 replicated groups read from 70 sample titles; they account for 70 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9023963 sgZBTB11 #1 DMSO, 5 hr, Rep1 sgZBTB11 #1 DMSO, 5 hr,
- GSM9023964 sgZBTB11 #1 DMSO, 5 hr, Rep2 sgZBTB11 #1 DMSO, 5 hr,
- GSM9023965 sgZBTB11 #1 DMSO, 5 hr, Rep3 sgZBTB11 #1 DMSO, 5 hr,
- GSM9023966 sgZBTB11 #1 DOX, 5 hr, Rep1 sgZBTB11 #1 DOX, 5 hr,
- GSM9023967 sgZBTB11 #1 DOX, 5 hr, Rep2 sgZBTB11 #1 DOX, 5 hr,
- GSM9023968 sgZBTB11 #1 DOX, 5 hr, Rep3 sgZBTB11 #1 DOX, 5 hr,
- GSM9023969 sgZBTB11 #2 DMSO, 5 hr, Rep1 sgZBTB11 #2 DMSO, 5 hr,
- GSM9023970 sgZBTB11 #2 DMSO, 5 hr, Rep2 sgZBTB11 #2 DMSO, 5 hr,
- GSM9023971 sgZBTB11 #2 DMSO, 5 hr, Rep3 sgZBTB11 #2 DMSO, 5 hr,
- GSM9023972 sgZBTB11 #2 DOX, 5 hr, Rep1 sgZBTB11 #2 DOX, 5 hr,
- GSM9023973 sgZBTB11 #2 DOX, 5 hr, Rep2 sgZBTB11 #2 DOX, 5 hr,
- GSM9023974 sgZBTB11 #2 DOX, 5 hr, Rep3 sgZBTB11 #2 DOX, 5 hr,
- GSM9023975 sgNS DMSO, 5 hr, Rep1 sgNS DMSO, 5 hr,
- GSM9023976 sgNS DMSO, 5 hr, Rep2 sgNS DMSO, 5 hr,
- GSM9023977 sgNS DMSO, 5 hr, Rep3 sgNS DMSO, 5 hr,
- GSM9023978 sgNS DOX, 5 hr, Rep1 sgNS DOX, 5 hr,
- GSM9023979 sgNS DOX, 5 hr, Rep2 sgNS DOX, 5 hr,
- GSM9023980 sgNS DOX, 5 hr, Rep3 sgNS DOX, 5 hr,
- GSM9023981 sgZBTB11 #1 DMSO, 1 day, Rep1 sgZBTB11 #1 DMSO, 1 day,
- GSM9023982 sgZBTB11 #1 DMSO, 1 day, Rep2 sgZBTB11 #1 DMSO, 1 day,
- GSM9023983 sgZBTB11 #1 DMSO, 1 day, Rep3 sgZBTB11 #1 DMSO, 1 day,
- GSM9023984 sgZBTB11 #1 DOX, 1 day, Rep1 sgZBTB11 #1 DOX, 1 day,
- GSM9023985 sgZBTB11 #1 DOX, 1 day, Rep2 sgZBTB11 #1 DOX, 1 day,
- GSM9023986 sgZBTB11 #1 DOX, 1 day, Rep3 sgZBTB11 #1 DOX, 1 day,
- GSM9023987 sgZBTB11 #2 DMSO, 1 day, Rep1 sgZBTB11 #2 DMSO, 1 day,
- GSM9023988 sgZBTB11 #2 DMSO, 1 day, Rep2 sgZBTB11 #2 DMSO, 1 day,
- GSM9023989 sgZBTB11 #2 DMSO, 1 day, Rep3 sgZBTB11 #2 DMSO, 1 day,
- GSM9023990 sgZBTB11 #2 DOX, 1 day, Rep1 sgZBTB11 #2 DOX, 1 day,
- GSM9023991 sgZBTB11 #2 DOX, 1 day, Rep2 sgZBTB11 #2 DOX, 1 day,
- GSM9023992 sgZBTB11 #2 DOX, 1 day, Rep3 sgZBTB11 #2 DOX, 1 day,
- GSM9023993 sgNS DMSO, 1 day, Rep1 sgNS DMSO, 1 day,
- GSM9023994 sgNS DMSO, 1 day, Rep2 sgNS DMSO, 1 day,
- GSM9023995 sgNS DOX, 1 day, Rep1 sgNS DOX, 1 day,
- GSM9023996 sgNS DOX, 1 day, Rep2 sgNS DOX, 1 day,
- GSM9023997 sgNS DOX, 1 day, Rep3 sgNS DOX, 1 day,
- GSM9023998 sgZBTB11 #1 DMSO, 3 days, Rep1 sgZBTB11 #1 DMSO, 3 day…
- GSM9023999 sgZBTB11 #1 DMSO, 3 days, Rep2 sgZBTB11 #1 DMSO, 3 day…
- GSM9024000 sgZBTB11 #1 DMSO, 3 days, Rep3 sgZBTB11 #1 DMSO, 3 day…
- GSM9024001 sgZBTB11 #1 DOX, 3 days, Rep1 sgZBTB11 #1 DOX, 3 days,
- GSM9024002 sgZBTB11 #1 DOX, 3 days, Rep2 sgZBTB11 #1 DOX, 3 days,
+ 30 more — browse all 70 samples with per-sample file links →
- GSE150043 Deeper insight into Pancreatic Ductal Adenocarcinoma (PDAC) survival heterogeneity using integrative analyses of individual and global transcriptome based networks 19 samples same disease briefing · shares pdac
- GSE101448 Microarray gene-expression data to identify a robust biomarker signature in PDAC and validate it in formalin-fixed paraffin-embedded tissue material. 43 samples same disease briefing · shares pdac
- GSE143256 Genomic Landscape and Therapeutic Targets of Adenosquamous Carcinoma of the Pancreas [CGH Microarray] 19 samples same disease briefing · shares targets
- GSE143584 Gene expression from laser capture microdissected epithelium and stroma during pancreatic carcinogenesis 366 samples same disease briefing
- GSE113616 Stromal Fibroblasts Drive Single Cell Heterogeneity in Pancreatic Cancer 189 samples same disease briefing
- GSE179351 Radiation Therapy Inhances Immunotherapy Response in Microsatellite-stable Colorectal and Pancreatic Adenocarcinoma in a Phase II Trial 54 samples same disease briefing
- GSE148188 NOXA dependent induction of apoptosis in pancreatic cancer cells 49 samples same disease briefing
- GSE273492 Selective NSD2 Inhibition Reveals an Epigenetic Vulnerability of KRAS-Driven Cancers [RNA-Seq] 36 samples same disease briefing
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.